Cellular Starting Materials Market Size Is Anticipated To Reach USD 4.84 Billion By 2030

 San Francisco, 10 Sep 2024: The Report Cellular Starting Materials Market Size, Share & Trends Analysis Report By Product (Leukopaks, Cells & Tissues), By Grade (GMP, Research-use), By End U-use, By Region, And Segment Forecasts, 2024 - 2030

The global cellular starting materials market size is anticipated to reach USD 4.84 billion by 2030, growingand is anticipated to expand at a CAGR of 22.74% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, rising investments, growing demand for cell and gene-based therapies, and technological innovations are expected to enhance the cellular starting materials market over the forecast period.

Cellular starting materials play a crucial role in supporting the development of cell and gene therapies. They are essential for both autologous and allogeneic cell therapies. As the field of cell therapy continues to expand rapidly, the demand for high-quality human cellular starting material is increases. Cell-based treatments are being investigated for a variety of conditions, including oncology, neurodegenerative disorders, and autoimmune diseases, leading to increased demand for different types of starting materials. Moreover, ongoing advancements in bioprocessing technologies, cell culture techniques, and quality control measures have enhanced the efficiency and scalability of manufacturing cellular starting materials, enabling companies to meet the increasing demand for these materials while maintaining product quality and consistency.

The COVID-19 pandemic had a significant impact on significantly impacted the market, with disruptions in supply chains and manufacturing processes leading to shortages and delays in manufacturing timelines. In the case of autologous cell therapies, the pandemic has caused extended patient collection times as patient-derived cells are used as starting material. However, the pandemic also underscored the importance of cell-based therapies and led to increased investments in the sector and accelerated regulatory approvals for some treatments.

However, strict regulations related to cell therapies present a major challenge to the cellular starting materials market. These regulations increase the costs of manufacturing cell and gene therapy products and obtaining the starting material. Various regions around the world have established specific regulations governing the collection, processing, and use of cellular starting material for cell therapies. Cellular therapy products meeting specific criteria outlined in 21 CFR 1271.10(a) are regulated solely as Human Cells, Tissues, and Cellular and & Tissue-Based Products (HCT/Ps) under Section 361 of the Public Health Service Act of the U.S.

Access Research Report of Cellular Starting Materials Market @ https://www.grandviewresearch.com/industry-analysis/cellular-starting-materials-market-report

Cellular Starting Materials Market Report Highlights

• Leukopaks dominated the product segment with a market share of 70.80% in 2023, as they are essential cellular starting materials for cell-based therapies.
• In 2023, GMP dominated the grade segment and held the largest market share in terms of revenue and is expected to grow at the highest CAGR of 22.78% over the forecast period.
• Pharmaceutical and biotechnology companies dominated the end-use market with the largest share of 51.04% in 2023, driven by their significant investment in research and development to bring novel treatments to market, leveraging cellular starting materials as key components in their manufacturing processes.
• Based on end use, tThe CMOs & CROs segment is anticipated to grow at the fastest CAGR due to their increasing adoption and investment in advanced research and manufacturing technologies.
• The North American region dominated the cellular starting materials market with a share of 43.49% owing to factors such as increasing investments in R&D activities, rising demand for cell-based therapies, and advanced healthcare infrastructure.

Cellular Starting Materials Market Report Scope

Report Attribute	Details
Market size value in 2024	USD 1.42 billion
Revenue forecast in 2030	USD 4.84 billion
Growth rate	CAGR of 22.74% from 2024 to 2030
Actual data	2018 - 2023
Forecast period	2024 - 2030

List of Key Players in the Cellular Starting Materials Market

• AllCells
• Charles River Laboratories
• BioIVT
• NMDP BioTherapies.
• CGT GLOBAL
• Excellos
• Anthony Nolan
• STEMCELL Technologies
• HumanCells Bio
• AcceGen

Access Press Release of Cellular Starting Materials Market @ https://www.grandviewresearch.com/press-release/global-cellular-starting-materials-market

About Grand View Research

Grand View Research is an India & U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services.

For More Information: https://www.grandviewresearch.com/horizon